Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical IncBMRN · filed May 11, 2023
- Accession no.
- 0001209191-23-028813
- Filed
- May 11, 2023
- Trade date
- Apr 28-May 10, 2023
- Filing delay
- 13 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.69M. It was filed 13 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Common Stock | AGrant or awardAcquired | +317 | $66.88 | +$21,200.96 | 426,213 | Direct | |
| May 9, 2023 | Common Stock | MOption exerciseAcquired | +30,000 | $67.81 | +$2,034,300 | 456,213 | Direct | |
| May 9, 2023 | Common Stock | SSaleDisposed | −13,626 | $94.22F3 | −$1,283,841.72 | 442,587 | Direct | |
| May 9, 2023 | Common Stock | SSaleDisposed | −14,964 | $95.49F4 | −$1,428,912.36 | 427,623 | Direct | |
| May 9, 2023 | Common Stock | SSaleDisposed | −1,410 | $95.90F5 | −$135,219 | 426,213 | Direct | |
| May 10, 2023 | Common Stock | MOption exerciseAcquired | +30,000 | $67.81 | +$2,034,300 | 456,213 | Direct | |
| May 10, 2023 | Common Stock | SSaleDisposed | −21,453 | $94.65F6 | −$2,030,526.45 | 434,760 | Direct | |
| May 10, 2023 | Common Stock | SSaleDisposed | −8,547 | $95.34F7 | −$814,870.98 | 426,213 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 9, 2023 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 99,130 | Direct | |
| May 9, 2023 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 69,130 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price in column 4 is the weighted average price. The price actually received ranged from $93.85 to $94.83. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.
- F4
The price in column 4 is the weighted average price. The price actually received ranged from $94.86 to $95.85. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.
- F5
The price in column 4 is the weighted average price. The price actually received ranged from $95.86 to $95.97. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.
- F6
The price in column 4 is the weighted average price. The price actually received ranged from $94.12 to $95.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.
- F7
The price in column 4 is the weighted average price. The price actually received ranged from $95.115 to $95.81. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.